UNIGE document Professional Article
previous document  unige:99034  next document
add to browser collection
Title

Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial

Authors
Huttner, Angela
Hatz, Christoph
van den Dobbelsteen, Germie
Abbanat, Darren
Hornacek, Alena
Frölich, Rahel
Dreyer, Anita M
Martin, Patricia
show hidden authors show all authors [1 - 26]
Published in The Lancet Infectious Diseases. 2017, vol. 17, no. 5, p. 528-537
Abstract Escherichia coli infections are increasing worldwide in community and hospital settings. The E coli O-antigen is a promising vaccine target. We aimed to assess the safety and immunogenicity of a bioconjugate vaccine containing the O-antigens of four E coli serotypes (ExPEC4V).
Keywords AdultAgedEscherichia coli Vaccines/administration & dosage/therapeutic useExtraintestinal Pathogenic Escherichia coli/isolation & purificationFemaleHumansImmunogenicity, VaccineMiddle AgedSingle-Blind MethodTreatment OutcomeUrinary Tract Infections/prevention & controlVaccination/methods
Identifiers
PMID: 28238601
Full text
Article (Published version) (408 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Groupe Harbarth Stephan (Staphylocoques dorés résistants à la méthicilline) (866)
Citation
(ISO format)
HUTTNER, Angela et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. In: The Lancet Infectious Diseases, 2017, vol. 17, n° 5, p. 528-537. https://archive-ouverte.unige.ch/unige:99034

104 hits

0 download

Update

Deposited on : 2017-11-15

Export document
Format :
Citation style :